The Effects of Dextroamphetamine on Brain Function

Sponsor
National Institute of Mental Health (NIMH) (NIH)
Overall Status
Completed
CT.gov ID
NCT00004556
Collaborator
(none)
108
1
323.8
0.3

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the effects of the drug dextroamphetamine on the brain function and mood of healthy volunteers.

Monoaminergic drugs are substances that affect the nervous system; these drugs can raise, hamper, or have no effect on brain function when given to healthy individuals. Different responses to a drug may be the result of genetic variations. This study will examine the effects of the monoaminergic drug dextroamphetamine on thought and sensorimotor processes while participants perform a variety of tasks.

Participants in this study will undergo a medical history, physical examination, blood tests, and an electrocardiogram (EKG). Women of reproductive potential will undergo a pregnancy test. Participants will be given either dextroamphetamine or placebo (an inactive solution) on two occasions separated by at least 3 to 7 days. Participants will then perform neuropsychological tests that will measure attention, problem solving, memory, and ability to complete simple motor tasks.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Neuropharmacological intervention with monoaminergic drugs in healthy subjects can either augment, have no effect, or hamper brain function. We hypothesize that these population differences might be related to differences (high vs. low) in monoaminergic synaptic function which may be due to specific allelic variations in monoamine system genes (e.g., various synaptic proteins, synthetic enzymes, etc.). We wish to examine the effect of dextroamphetamine, a non-specific monoaminergic drug, on cognitive efficiency while subjects perform a variety of tasks including memory challenges with increasing cognitive load and varying rewards, selective attention and emotional processing. Further, in collaboration with other NIMH neuroimaging protocols, we wish to examine the neurophysiological correlates of these effects. We believe this protocol will provide a matrix for many investigations to elucidate important neurophysiological mechanisms that underlie normal cognition and cognitive efficiency. It is anticipated that these studies would be of potential 'pharmacogenetic' importance with regard to individual differences in the metabolism of monoaminergic drugs in normal health, aging and in disease.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    108 participants
    Official Title:
    Mechanisms of Individual Variation of Dextroamphetamine Effects in Normal Human Subjects
    Study Start Date :
    Sep 30, 1991
    Study Completion Date :
    Sep 25, 2018

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years to 45 Years
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      • INCLUSION CRITERIA:

      Normal volunteers will be recruited exclusively from among individuals who have volunteered for studies under protocol 95-M-0150 as normal control subjects and for whom genetic data is already available. Subjects will satisfy the inclusion/exclusion criteria for that protocol before being given an opportunity to volunteer under this protocol. Here we detail criteria that are specific to this protocol, per se.

      Inclusion criteria:
      1. Prior participation as a normal volunteer under NIH protocol # 95-M-0150.

      2. No Axis I or Axis II diagnosis.

      3. Age range: 18-45 years.

      EXCLUSION CRITERIA:
      1. Subjects with an Axis I or II disorder will be excluded.

      2. Subjects with a history of cardiovascular disease and other medical illnesses, substance abuse or recreational drug use, and hypertension will be excluded. An electrocardiogram, blood pressure and pulse rate will be checked on all subjects prior to participation in the study.

      3. Pregnant women. Women of childbearing potential will undergo a urine pregnancy test the day of the study and screened by history for the possibility of pregnancy.

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland United States 20892

      Sponsors and Collaborators

      • National Institute of Mental Health (NIMH)

      Investigators

      • Principal Investigator: Karen F Berman, M.D., National Institute of Mental Health (NIMH)

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      Responsible Party:
      National Institute of Mental Health (NIMH)
      ClinicalTrials.gov Identifier:
      NCT00004556
      Other Study ID Numbers:
      • 910230
      • 91-M-0230
      First Posted:
      Feb 9, 2000
      Last Update Posted:
      Sep 28, 2018
      Last Verified:
      Sep 25, 2018
      Studies a U.S. FDA-regulated Device Product:
      No
      Keywords provided by National Institute of Mental Health (NIMH)

      Study Results

      No Results Posted as of Sep 28, 2018